Seroatlas · Human Serome Atlas

LRRC52

Leucine-rich repeat-containing protein 52

Also known as: FLJ25811, LRC52_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N7C0
Gene: LRRC52
Ensembl: ENSG00000162763
Chromosome: 1
Canonical length: 313 aa
Protein class: Predicted membrane proteins

OverviewNCBI Gene

Enables potassium channel activator activity; transmembrane transporter binding activity; and voltage-gated potassium channel activity. Involved in positive regulation of voltage-gated potassium channel activity and potassium ion transmembrane transport. Part of voltage-gated potassium channel complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

313 residues, UniProt reviewed canonical sequence.

>Q8N7C0|LRRC52
     1  MSLASGPGPG WLLFSFGMGL VSGSKCPNNC LCQAQEVICT GKQLTEYPLD IPLNTRRLFL
    61  NENRITSLPA MHLGLLSDLV YLDCQNNRIR EVMDYTFIGV FKLIYLDLSS NNLTSISPFT
   121  FSVLSNLVQL NIANNPHLLS LHKFTFANTT SLRYLDLRNT GLQTLDSAAL YHLTTLETLF
   181  LSGNPWKCNC SFLDFAIFLI VFHMDPSDDL NATCVEPTEL TGWPITRVGN PLRYMCITHL
   241  DHKDYIFLLL IGFCIFAAGT VAAWLTGVCA VLYQNTRHKS SEEDEDEAGT RVEVSRRIFQ
   301  TQTSSVQEFP QLI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LRRC52 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 16 nTPM

Expression across tissuesHPA

Tissue

testis: 16 nTPM
parathyroid gland: 3.8 nTPM
choroid plexus: 2.9 nTPM
skeletal muscle: 1.2 nTPM
heart muscle: 0.4 nTPM
kidney: 0.3 nTPM

Single-cell type

early spermatids: 235 nCPM
late primary spermatocytes: 96 nCPM
late spermatids: 43 nCPM
retinal ganglion cells: 16 nCPM
myonuclei: 8.2 nCPM
distal convoluted tubule cells: 6.5 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

choroid plexus: 2.7 nTPM
midbrain: 0.9 nTPM
medulla oblongata: 0.7 nTPM
pons: 0.3 nTPM
cerebellum: 0.1 nTPM
hippocampal formation: 0.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.66
gnomAD pLI: 0
gnomAD missense Z: 0.04
DepMap mean gene effect: 0.18
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LRRC52 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LRRC52 as an antibody target. Whether an autoantibody or antibody against LRRC52 could matter depends on whether native LRRC52 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LRRC52 is annotated at the cell surface, where native LRRC52 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LRRC52 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...